NCT06770504View on ClinicalTrials.gov

A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Autoimmune Hemolytic AnemiaAnti-CD19 STAR T-cell TherapyFailure ≥3 Lines of Therapies
Interventions
BIOLOGICAL

YTS109

In this study, subjects will receive YTS109 Cell Injection(0.5-1E6 STAR+T cell/kg) once.

All Listed Sponsors
collaborator

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER